Cited by 22Lysosomal Storage Disorders ResearchNeuroinflammation and Neurodegeneration MechanismsGlycogen Storage Diseases and Myoclonus

Myeloid cell–specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease

Dinkel, Lina, Hummel, Selina, Zenatti, Valerio, Malara, Mariagiovanna, Tillmann, Yannik, Colombo, Alessio, Monasor, Laura Sebastian, Suh, Jung H. +35 more·2024·Science Translational Medicine

Abstract

Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.adl4616

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Still being checked.

Authors
Dinkel, L., Hummel, S., Zenatti, V., Malara, M., Tillmann, Y., Colombo, A., Monasor, L. S., Suh, J. H., Logan, T., Roth, S., Paeger, L., Hoffelner, P., Bludau, O., Schmidt, A., Müller, S. A., Schifferer, M., Nuscher, B., Njavro, J. R., Prestel, M., Bartos, L. M., Wind-Mark, K., Slemann, L., Hoermann, L., Kunte, S. T., Gnörich, J., Lindner, S., Simons, M., Herms, J., Paquet, D., Lichtenthaler, S. F., Bartenstein, P., Franzmeier, N., Liesz, A., Grosche, A., Bremova-Ertl, T., Catarino, C., Beblo, S., Bergner, C., Schneider, S. A., Strupp, M., Di Paolo, G., Brendel, M., & Tahirovic, S.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • LMU Klinikum (DE)
  • German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
  • Denali Therapeutics (United States) (US)
  • Ludwig-Maximilians-Universität München (DE)
  • Department of Neurology, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
  • University Hospital Leipzig (DE)
  • Denali Therapeutics Inc., South San Francisco, CA 94080, USA.
Corresponding author
  • Dinkel, Lina
  • Hummel, Selina
  • Brendel, Matthias
Venue
Science Translational Medicine
Published
2024-12-04
Volume
16
Issue
776
Pages
eadl4616-eadl4616
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4405022609
Cited by
22
References
101
Citations by year
2026: 9 · 2025: 13
FWCI
5.26
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • DZNE Pub (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Rheumatology › Glycogen Storage Diseases and Myoclonus
Keywords
Niemann-Pick disease type C, NPC1, microglia, lysosomal storage disease, cholesterol, cholesterol esters, bis(monoacylglycero)phosphate, translocator protein (TSPO), TSPO PET imaging, neurodegeneration, neurofilament light chain, astrocyte activation, N-acetyl-L-leucine, disease biomarkers
MeSH terms
Niemann-Pick C1 Protein, Animals, Disease Models, Animal, Gliosis, Humans, Microglia, Receptors, GABA, Myeloid Cells, Intracellular Signaling Peptides and Proteins, Mice, Niemann-Pick Disease, Type C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review